NDLI: Genetics and pharmacogenetics of the leukotriene pathway.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Tantisira, Kelan G. Drazen, Jeffrey M.
Description	Country affiliation: United States Author Affiliation: Tantisira KG ( Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA. rekgt@channing.harvard.edu)
Abstract	Leukotrienes are now established contributors to the inflammatory process in asthma, and leukotriene modifiers are mainstays in the therapy of asthma. This review focuses on published association studies implicating the role of leukotriene pathway genes in asthma pathogenesis and treatment response, specifically focusing on those genetic variants associated with asthma affection status, the development of aspirin-exacerbated respiratory disease, and pharmacogenetic response. Although published studies have been limited by small sample sizes and a lack of independent replication, multiple loci within multiple leukotriene pathway genes have now been associated in more than 1 study related to asthma or asthma treatment response. Those specific variants include 2 variants in the 5-lipoxygenase gene (ALOX5) that are both associated with response to 5-lipoxygenase inhibition and to leukotriene receptor antagonists, variants in genes encoding the 2 established cysteinyl leukotriene receptor antagonists (CYSLTR1 and CYSLTR2) that are both associated with asthma susceptibility in at least 2 independent populations, and a leukotriene C(4) synthase promoter polymorphism (LTC4s) that has been associated with asthma affection status and asthma-exacerbated respiratory disease. Despite these successes, genetic investigations into this pathway remain in their formative stages. Future studies aimed at providing a broader scope of investigation through increased sample sizes and through genome-wide approaches are needed.
File Format	HTM / HTML
ISSN	00916749
e-ISSN	10976825
DOI	10.1016/j.jaci.2009.06.035
Journal	Journal of Allergy and Clinical Immunology
Issue Number	3
Volume Number	124
Language	English
Publisher	Elsevier
Publisher Date	2009-09-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Immunology Anti-asthmatic Agents Therapeutic Use Arachidonate 5-lipoxygenase Genetics Asthma Drug Therapy Leukotriene Antagonists Leukotrienes Receptors, Leukotriene Animals Immunology Metabolism Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Leukotriene modifiers for asthma treatment.

Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma.

The role of pharmacogenomics in improving the management of asthma.

Pharmacogenetics of asthma.

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma.

Eosinophilic asthma: insights into the effects of reducing IL-5 receptor-positive cell levels.

Biologics in asthma--the next step toward personalized treatment.

Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease.

Therapeutic strategies to reduce asthma exacerbations.

Genetics and pharmacogenetics of the leukotriene pathway.

Similar Documents

Leukotriene modifiers for asthma treatment.

Efficacy of leukotriene receptor antagonists and synthesis inhibitors in asthma.

The role of pharmacogenomics in improving the management of asthma.

Pharmacogenetics of asthma.

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma.

Eosinophilic asthma: insights into the effects of reducing IL-5 receptor-positive cell levels.

Biologics in asthma--the next step toward personalized treatment.

Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease.

Therapeutic strategies to reduce asthma exacerbations.

Genetics and pharmacogenetics of the leukotriene pathway.